USA – Acuamark Diagnostics, a NYC-based early cancer detection company, closed an $11.3m Series A funding round.
The round was led by the office of Claudio Del Vecchio* and the Del Vecchio Family Foundation, and it was joined by Bruker Corporation (NASDAQ: BRKR) as a new investor. Claudio Del Vecchio has joined AcuamarkDx’s Board of Directors. With the Series A proceeds, the company intends to scale its sample collections and add a number of key building blocks to its organization.Led by Co-founder and CEO Dr. Bernard Peperstraete, AcuamarkDx is a biotechnology company focused on developing innovative technology for improved and cost-effective blood-based early-cancer screening for single cancer early detection and multi-cancer early detection. * Claudio Del Vecchio is an international business entrepreneur and industry leader. He is a skilled executive and a seasoned public Board member. The Del Vecchio family founded the Luxottica Group where Mr. Del Vecchio was an Executive Board Director for several years, ran its US operations, and oversaw its public offering on the New York Stock Exchange. Subsequently, Mr. Del Vecchio acquired Brooks Brothers which he ran for 20 years until the COVID Pandemic.20/07/2022
